Goldman Sachs Group Inc. Sells 47,412 Shares of Phibro Animal Health Corporation $PAHC

Key Points

• Goldman Sachs Group Inc. reduced its holdings in Phibro Animal Health Corporation by 19.4%, selling 47,412 shares, and now owns approximately 0.49% of the company.
• Analysts have mixed ratings for Phibro Animal Health, with a consensus rating of "Reduce" and an average price target of $28.40, while recent reports set targets ranging from $24.00 to $35.00.
• Phibro Animal Health announced a quarterly dividend of $0.12, representing an annual yield of 1.2%, with a payout ratio of 40.68%.

Goldman Sachs Group Inc. reduced its stake in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 19.4% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 196,830 shares of the company's stock after selling 47,412 shares during the quarter. Goldman Sachs Group Inc. owned about 0.49% of Phibro Animal Health worth $4,204,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Man Group plc bought a new position in Phibro Animal Health in the 4th quarter valued at about $501,000. GAMMA Investing LLC increased its holdings in shares of Phibro Animal Health by 2,011.4% during the first quarter. GAMMA Investing LLC now owns 36,718 shares of the company's stock worth $784,000 after purchasing an additional 34,979 shares during the period. LPL Financial LLC increased its holdings in shares of Phibro Animal Health by 46.8% during the first quarter. LPL Financial LLC now owns 128,335 shares of the company's stock worth $2,741,000 after purchasing an additional 40,889 shares during the period. Lazard Asset Management LLC increased its holdings in shares of Phibro Animal Health by 2,739.7% during the fourth quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock worth $34,000 after purchasing an additional 1,589 shares during the period. Finally, Nuveen Asset Management LLC increased its holdings in shares of Phibro Animal Health by 21.4% during the fourth quarter. Nuveen Asset Management LLC now owns 588,001 shares of the company's stock worth $12,348,000 after purchasing an additional 103,618 shares during the period. 99.34% of the stock is owned by institutional investors.

Insider Activity at Phibro Animal Health

In related news, CEO Jack Bendheim sold 3,520 shares of the business's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $41.29, for a total transaction of $145,340.80. Following the transaction, the chief executive officer directly owned 41,880 shares in the company, valued at approximately $1,729,225.20. The trade was a 7.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 50.07% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

PAHC has been the topic of several recent research reports. BNP Paribas Exane raised shares of Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 target price on the stock in a report on Monday, June 16th. BNP Paribas raised shares of Phibro Animal Health to a "hold" rating in a research note on Monday, June 16th. Zacks Research cut shares of Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 28th. JPMorgan Chase & Co. raised shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $25.00 to $35.00 in a research note on Monday, July 7th. Finally, Bank of America lifted their price objective on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research note on Friday, August 29th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Reduce" and an average price target of $28.40.

Phibro Animal Health Stock Down 1.7%

PAHC traded down $0.68 during midday trading on Friday, hitting $39.86. The company had a trading volume of 554,817 shares, compared to its average volume of 278,002. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $41.57. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46. The company has a market capitalization of $1.62 billion, a price-to-earnings ratio of 33.78, a PEG ratio of 1.15 and a beta of 0.89. The stock's 50 day moving average price is $32.68 and its 200 day moving average price is $25.96.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its earnings results on Wednesday, August 27th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.52 by $0.05. The company had revenue of $378.70 million during the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, research analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 24th. Stockholders of record on Wednesday, September 3rd will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, September 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. Phibro Animal Health's payout ratio is presently 40.68%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.